Abstract
This critique of the practice of testosterone replacement therapy for HIV+ individuals and of Wagner, Rabkin, and Rabkin's (1997) research on this topic focuses on (a) the dubious ethics of stimulating sexual desire and sexual function in persons who carry a fatal, sexually borne pathogen, (b) our very limited ability to ensure that testosterone replacement therapy for HIV+ persons will not pose significant danger to uninfected persons, and (c) the relative importance of quality of life versus protection of life considerations in research and therapy in the HIV/AIDS area.